Mortality Risk Conferred by Small Elevations of Creatine Kinase-MB Isoenzyme after Percutaneous Coronary Intervention

Journal of the American College of Cardiology

Volumn 42, Issue 8, 2003, Pages 1406-1411

  Ioannidis, John P A ^a,b,d   Karvouni, Evangelia ^c   Katritsis, Demosthenes G ^c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Athens Euroclinic   (Greece)

^d UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE MB; ISOENZYME;

ADULT; AGED; ANGIOPLASTY; ARTICLE; ATHERECTOMY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY SURGERY; CORONARY STENT; DEATH; EXCIMER LASER; FEMALE; FOLLOW UP; HUMAN; LASER ANGIOPLASTY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; POPULATION RESEARCH; POSTOPERATIVE CARE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 0142075775     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)01044-1     Document Type: Article

References (31)

1. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000;101:570-80.
2. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241-51.
3. Johansen O, Brekke M, Stromme JH, et al. Myocardial damage during percutaneous transluminal coronary angioplasty as evidenced by troponin T measurements. Eur Heart J 1998;19:112-7.
4. Bonz AW, Lengenfelder B, Strotmann J, et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J Am Coll Cardiol 2002; 21;40:662-8.
5. Akkerhuis KM, Alexander JH, Tardiff BE, et al. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? Circulation 2002;105:554-6.
6. Stone GW, Mehran R, Dangas G, et al. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation 2001;104:642-7.
7. Colombo A, Stankovic G. Nothing is lower than 0, and 3 is closer to 0 than to 5 - medicine is not arithmetic. Eur Heart J 2002;23:840-2.
8. Ellis SG, Chew D, Chan A, et al. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation 2002;106:1205-10.
9. Pettiti D. Meta-Analysis, Decision Analysis and Cost-Effectiveness Analysis. 2nd edition. New York, NY: Oxford University Press, 1999.
10. Kini A, Kini S, Marmur JD, et al. Incidence and mechanism of creatine kinase-MB enzyme elevation after coronary intervention with different devices. Catheter Cardiovasc Intervent 1999;48:123-9.
11. Brener SJ, Lytle BW, Schneider JP, Ellis SG, Topol EJ. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol 2002;40:1961-7.
12. Harrington RA, Lincoff AM, Califf RM, et al. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). J Am Coll Cardiol 1995;25: 1693-9.
13. Kugelmass AD, Cohen DJ, Moscucci M, et al. Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. Am J Cardiol 1994;74: 748-54.
14. Baim DS, Cutlip DE, Sharma SK, et al. Final results of the Balloon vs Optimal Atherectomy Trial (BOAT). Circulation 1998;97:322-31.
15. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA 1997;277:461-6.
16. Abdelmeguid AE, Ellis SG, Sapp SK, Whitlow PL, Topol EJ. Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Am Heart J 1996;131:1097-105.
17. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996;94:1528-36.
18. Abdelmeguid AE, Whitlow PL, Sapp SK, Ellis SG, Topol EJ. Long-term outcome of transient, uncomplicated in-laboratory coronary artery closure. Circulation 1995;91:2733-41.
19. Saucedo JF, Mehran R, Dangas G, et al. Long-term clinical events following creatine kinase-myocardial band isoenzyme elevation after successful coronary stenting. J Am Coll Cardiol 2000;35: 1134-41.
20. Tardiff BE, Califf RM, Tcheng JE, et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention: IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. J Am Coll Cardiol 1999;33:88-96.
21. Simoons ML, van den Brand M, Lincoff M, et al. Minimal myocardial damage during coronary intervention is associated with impaired outcome. Eur Heart J 1999;20:1112-9.
22. Gruberg L, Mehran R, Waksman R, et al. Creatine kinase-MB fraction elevation after percutaneous coronary intervention in patients with chronic renal failure. Am J Cardiol 2001;87:1356-60.
23. Fuchs S, Kornowski R, Mehran R, et al. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol 2000;85:1077-82.
24. Dangas G, Mehran R, Feldman D, et al. Postprocedure creatine kinase-MB elevation and baseline left ventricular dysfunction predict one-year mortality after percutaneous coronary intervention. Am J Cardiol 2002;89:586-9.
25. Lincoff AM, Tcheng JE, Califf RM, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/ IIIa blockade with abciximab: one-year outcome in the EPILOG trial: Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation 1999;99:1951-8.
26. Narins CR, Miller DP, Califf RM, Topol EJ. The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial: Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol 1999;33:647-53.
27. Hong MK, Mehran R, Dangas G, et al. Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. Circulation 1999;100:2400-5.
28. Jeremias A, Albirini A, Ziada KM, et al. Prognostic significance of creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal dysfunction. Am Heart J 2002;143: 1040-5.
29. Brener SJ, Ellis SG, Schneider J, Topol EJ. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J 2002;23: 869-76.
30. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36: 959-69.
31. Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/ IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003;41:26-32.